Table 2.
Laboratory Findings of Patients With COVID-19 During Hospitalization [Median (IQR)]
| Variable | Normal Range | Mild (n = 19) | Sever (n = 18) | Critical (n = 13) | P Value |
|---|---|---|---|---|---|
| Course of disease, day | / | 7 (4–11) | 7 (6–7) | 6 (3–8) | .567 |
| Lymphocyte count, ×109/L | 1.1–3.2 | 1.9 (1.4–2.3) | 0.63 (0.56–0.72)a | 0.39 (0.30–0.53)b,c | <.001 |
| Lymphocyte, % | 20–50 | 21 (17–26) | 7 (5–11)a | 5 (3–7) | <.001 |
| Red blood cell count, ×1012/L | 3.8–5.1 | 4.1 (3.6–4.6) | 4.2 (3.9–4.8) | 4.4 (4.0–4.7) | .270 |
| Hemoglobin, g/L | 115–150 | 127 (112–145) | 132 (117–146) | 134 (121–150) | .270 |
| D-dimer, µg/mL | 0–1 | 0.34 (0.27–0.67) | 1.07 (0.48–1.47)a | 9.05 (1.81–28.8)b,c | <.001 |
| Fibrinogen (FIB), g/L | 0–5 | 3.1 (2.0–4.0) | 4.8 (3.3–5.6)a | 16.3 (6.0–49.2)b,c | <.001 |
| CRP, mg/L | 0–5 | 3.6 (1.4–6.0) | 41.8 (13.1–70.7)a | 104.6 (51.0–165.1)b,c | <.001 |
| SAA, mg/L | 0–10 | 57 (27–121) | 501 (313–721)a | 1359 (499–1795)b,c | <.001 |
| PCT, ng/mL (PCT < 0.25) | 0.04–0.25 | 19 (100) | 15 (83.3) | 7 (53.8) | .003 |
| Serum iron, µmol/L | 7.8–32.3 | ||||
| Pretreatment | / | 6.6 (5.4–10.9) | 4.9 (4.0–8.1)a | 5.2 (2.6–7.3) | .320 |
| Posttreatmentt | / | 21.6 (16.3–26.6)d | 17.9 (11.6–22.8)d | 11.8 (7.8–21.7)c,d | .198 |
| BNP, ng/L | 0–125 | 68 (34–189) | 545 (290–890)a | 962 (223–1457)b,c | <.001 |
| Creatine kinase (CK), U/L | 25–200 | 68 (51–92) | 85 (38–175) | 78 (71–311) | .679 |
| Lactic dehydrogenase (LDH), U/L | 109–245 | 190 (164–244) | 297 (202–377)a | 398 (291–535)b,c | <.001 |
| PH (blood gas analysis) | 7.35–7.45 | 7.40 (7.38–7.45) | 7.44 (7.41–7.46) | 7.41 (7.39–7.47) | .641 |
| PaO2, mmHg | 80–100 | 104 (79–135) | 100 (74–132) | 69 (54–134) | .198 |
| Oxygen saturation | 95–97 | 98 (96–99) | 98 (96–99) | 95 (89–99) | .893 |
| Creatinine, µmol/L | 44–120 | 60 (49–66) | 66 (56–96) | 66 (45–78) | .320 |
| Urea nitrogen, mmol/L | 3.5–7.2 | 3.5 (2.6–4.6) | 4.6 (3.7–5.0)a | 6.2 (4.5–7.1)b,c | .016 |
| ALT, U/L | 5–40 | 26 (15–34) | 33 (19–72) | 34 ( (21–77) | .679 |
| AST, U/L | 8–40 | 34 (27–45) | 43 (35–52) | 50 (38–74)c | .094 |
| TNI, µg/L | 0.01–0.023 | .126 | |||
| TNI <0.01 | / | 18 (94.7) | 16 (88.9) | 9 (69.2) | |
| TNI >0.023 | / | 1 (5.3) | 2 (11.1) | 4 (30.8) | |
| Myohemoglobin, µg/L | 23–112 | 18 (10–25) | 34 (13–43)a | 52 (35–79)b,c | <.001 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; COVID-19, coronavirus 2019; CRP, C-reactive protein; IQR, interquartile range; PaO2, partial pressure of oxygen; PCT, procalcitonin; PH, potential of hydrogen; SAA, serum amyloid A; TNI, troponin I.
NOTE: P < .05 was considered significant, significant values are shown in bold.
aP < .05, compared with mild group.
bP < .05, compared with severe group.
cP < .05, compared with mild group.
dP < .05 compared with pretreatment.